

SUBJECT INDEX

- A69024, 911
 Acetaldehyde, 55
 Acetylcholine, 25, 563, 781, 835
 Acetylcholinesterase, 211, 337
 Acetylcholinesterase inhibition, 929
 ACh levels, 437
 ACTH, 765
 Active avoidance, 31
 Activity, 85, 821, 883
 Activity cages, 513
 Acute and chronic administration, 313
 Acute cocaine administration, 923
 Acute opiate withdrawal, 329
 Acute stress, 373
 Addictive potential, 873
 Adenine, 321
 Adenosine, 97, 155, 345, 883
 5-ADMP, 737
 Adrenergic receptor: α_2 , 383
 α_1 -Adrenoceptors, 167, 437
 α_2 -Adrenoceptors, 167
 Aerosol, 265
 AF102B, 289
 Affect, 509
 Aggression (isolation-induced), 729
 Aggressive behavior, 167
 Aging, 79, 297, 1015
 Alaproclate, 25
 Alcohol, 5, 443, 513, 531
 Alcohol-ethyl, 457
 Allodynia, 695
 Alpha-2 adrenoceptors, 1015
 Alpha₂-antagonists, 313
 Alzheimer's disease, 287, 563, 841, 991
 Amino acids, 115, 205
 3-Amino-1,2,4-triazole, 55
 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclo-
 penta-(b)-quinoline monohydrate hydro-
 chloride (NIK-247), 499
 Amitriptyline, 553
 Ammonia, 115
 Amphetamine, 61, 71, 755, 877, 963
 Amygdala, 903
 Anagrams, 265
 Analeptic, 449
 Analgesia, 591, 873
 Analgesics, 873
 Anesthesia, 665
 Anhedonia, 895
 Animal model, 1, 49, 421
 Anorexia, 115, 963
 Anosmia, 983
 Antagonism, 129
 Anticholinergic, 935
 Anticholinesterase, 305, 613
 Anticonvulsant, 711
 Antidepressant, 1, 105, 553, 769
 Antiepileptic drugs, 205
 Antinociception, 591
 Anxiety, 325, 367, 521, 803
 Anxiogenic β -carboline, 791
 Anxiolysis, 321
 Anxiolytic, 275, 367, 977
 Apomorphine, 61, 545, 699
 Apropen, 453
 Arterial pressure, 1029
 Assay method, 495
 Associative tolerance, 279
 Ataxia, 257
 Atenolol, 597
 Atipamezole, 1015
 Atropine, 453, 613
 Aversion, 683
 Avoidance learning, 197
 Barbitol, 705
 Barbiturate, 305
 Basal forebrain (BF) lesion, 997
 Bay K 8644, 325
 Behavior, 79, 415, 473, 487, 947
 Behavioral effects, 453
 Behavioral pattern, 61
 Behavioral thermoregulation, 21, 809
 Behavioral tolerance, 351
 Benactyzine, 453
 Benzodiazepine, 129, 559, 671, 711, 859,
 903, 1021
 Benzodiazepine inverse agonist, 803
 Benzodiazepine rebound, 351
 Benzodiazepine receptors, 791
 Benzodiazepine synergism, 525
 Benzodiazepine-GABA_A receptor complex,
 553
 Beta-adrenoceptors, 597
 Beta-endorphin, 201
 Bicuculline, 653
 Biting, 695
 BMY-7378, 729
 Body, 305
 Body temperature, 249, 535, 1003
 Brain histamine, 847
 Brain lesions, 1033
 Brain regions, 191, 337
 Brain temperature, 457
 Brain-evoked potential, 889
 Bretazenil, 129
 Bromocriptine, 367
 Bulimia nervosa, 421
 Buprenorphine, 487
 Buspirone, 275, 729
 Butorphanol tartrate, 421
 C57BL/6J mice, 821
 Caffeine, 97, 525, 883
 Calcium channel inhibitors, 743
 Calcium channels, 325, 781
 Calcium-activated neutral proteases, 495
 Calpain, 495
 cAMP phosphodiesterase inhibitors, 321
 Cancer, 115
 Carbamate, 929
 β -Carbolines, 559
 2 β -Carbomethoxy-3 β (4-fluorophenyl)tro-
 pane, 1011
 Cat, 137, 941
 Catalase, 55
 Catecholamines, 79, 313, 963
 Cathine, 549
 Caudate nucleus, 619
 CCK, 581
 Cellular tolerance, 249, 257
 Central nervous system depression, 653
 Centrally acting cholinesterase inhibitor, 499
 Cerebral cortex, 553
 Cerebral microdialysis, 619
 cGMP, 379
 Chemical number 72026-83-6, 161
 Chewing behavior, 877
 Chloral hydrate, 665
 Chlordiazepoxide, 275, 597, 859
 Cholecystokinin, 201, 581
 Choline acetyltransferase, 337
 Choline precursors, 835
 Cholinergic, 449
 Cholinergic drugs, 49
 Cholinesterase inhibitors, 865
 Chronic administration, 437
 Chronic cocaine administration, 923
 Chronic diazepam and plasma protein
 binding, 395
 Chronic flunitrazepam and plasma protein
 binding, 395
 Chronic stress, 293
 Chronic treatment, 711
 Ciprofloxacin, 587
 Circling behavior, 97
³⁶Cl⁻ uptake, 553
 Classical conditioning, 183, 503
 Clomipramine, 293
 Clonazepam, 671, 1021
 Clonidine, 79, 167, 791, 795
 Clorgyline, 91
 Cocaethylene, 531
 Cocaine, 133, 137, 269, 503, 525, 531,
 625, 723, 799, 911, 941, 1011
 Cocaine analog, 1011
 Cocaine recognition sites, 1011
 Cognition, 287, 865
 Colonic temperature, 37
 Common chemical sense, 983
 Compensatory response, 279
 Concept learning, 829
 Conditioned drug effects, 1033
 Conditioned place preference, 143, 509,
 873, 143
 Conditioned taste aversion, 859
 Conditioning, 15
 Consummatory negative contrast, 803
 Consumption, 21
 Control of eating, 1025
 Convulsions, 109
 Copulation, 177
 Core temperature, 305, 929
 Corpus striatum, 109, 769
 Cortex, 437
 Corticosterone, 91, 373, 765
 Corticosterone response, 149
 CPP, 971, 977
 Cross-tolerance, 705, 711
 Cued navigation, 25
 CV 205-502, 465
 Cysteic acid, 653
 Cysteine sulfinic acid, 653
 Cytokine, 535
 D1, 449, 465
 D2, 449, 465
 D1 dopamine antagonists, 799

- D1 receptor, 677, 911, 955
 D2 agonists, 109
 D2 autoreceptor, 545
 D2 dopamine antagonists, 799
 D2 receptor, 123, 677, 911
 D₂ dopamine receptors, 105
 D₁ receptors, 769
 DA agonist, 367
 DA antagonist, 367
 [D-Ala²,Leu⁵,Cys⁶]-enkephalin (DALCE), 429
 Day-old chicks, 717
 Delayed matching-to-sample, 79, 817, 935
 Delayed nonmatching, 1015
 Delayed response, 79
 Delta opioid receptor, 429
 Dementia, 287, 865
 Deoxycorticosterone acetate, 171
 2-Deoxy-D-glucose feeding, 429
 Dependence, 329, 659
 L-Deprenyl, 297
 Depression, 1
 Deprivation, 211
 Deprivation feeding, 429
 Desipramine, 43, 167
 Desmethyl Diazepam, 149
 Desmethylimipramine, 1, 293
 Development, 883
 Dexmedetomidine, 383
 Dextromethorphan, 575
 DFP, 851
 DHPG, 791
 Diabetes, 541
 Diabetic, 383
 Diaphragm, 137
 Diazepam, 191, 559, 587, 683, 903
 Diazepam dependence in dogs, 395
 Diazepam plasma and brain levels, 395
 Differential outcomes effect, 817
 Dihydropyridines, 743
 Diisopropylfluorophosphate, 305
 Directed forgetting, 935
 Discriminated taste aversion, 859
 Discriminative stimulus, 487
 Dog, 313
 DOI, 605
 DOPAC/DA ratio, 1025
 Dopamine, 71, 97, 115, 123, 155, 361, 469, 549, 619, 677, 769, 773, 895, 911, 955, 963, 1033
 Dopamine and motor function, 955
 Dopamine antagonist, 955
 Dopamine D₁ receptors, 699
 Dopamine D₂ receptors, 699
 Dopamine D2 receptor, 177
 Dopamine receptor, 465, 517
 Dopamine release, 877
 Dopaminergic system, 545
 Dose-dependent, 143
 Dose-response, 841
 Doxepine, 293
 Drug discrimination, 5, 129, 521, 549, 859, 971
 Drug tolerance, 279
 DSP-4, 809
 Dystonia, 49
 Eating, 559, 1003
 Ecstasy, 813
 EEG, 415, 851
 EEG spectral analysis, 665
 Electric footshock, 379, 597
 Electric footshock-induced fighting behavior, 293
 Electrical brain stimulation, 683
 Endogenous satiety agent, 161
 Endopeptidase, 119
 Energy expenditure, 215
 Enkephalins, 119
 Environmental specificity, 279
 Ephedrine, 755
 Epilepsy, 415, 683, 825
 Epileptiform bursting, 119
 Erythrocyte membrane, 443
 Escape reaction, 809
 Essential tremor, 345
 Estrogen/progesterone, 737
 Ethanol, 5, 37, 55, 85, 325, 653, 659, 803, 821, 917
 Ethanol sensitivity, 457
 Excitatory amino acid, 31, 155
 Exercise, 337, 821
 Explicit unpairing, 279
 Exploratory behavior, 877
 Eye irritation, 983
 Fats, 1025
 Feeding, 1003
 Feeding behavior, 559
 Female rats, 737
 Females, 695
 Fenfluramine, 91, 549
 Fetal alcohol effects, 423
 Fetal Alcohol Syndrome (FAS), 389
 Fever, 535
 FG 7142, 791
 Flumazenil, 395
 Flunitrazepam dependence in dogs, 395
 Flunitrazepam plasma and brain levels, 395
 Fluoroquinolones, 587
 (³H)-FNZ binding, 379
 Food and water consumption, 161
 Food intake, 313, 1003
 Food restriction, 421
 Food reward, 955, 1025
 Forced swim test, 373
 Forgetting, 437
 Free feeding, 429
 Free radicals, 649
 Frontal cortex, 841
 GABA, 345, 473, 653, 765
 Gamma-aminobutyric acid, 205
 Gangliosides, 825
 Gastric transit, 755
 Gastric ulcer, 847
 Generalization, 129
 Genital responses, 177
 Gepirone, 729
 Glucose, 373
 d-Glucose, 383
 L-Glutamic acid diethyl ester, 829
 Glycine, 31
 Gonadectomy, 923
 Gray wolf, 559
 Grooming, 699
 Growth, 883
 H₁ and H₂ receptor, 847
 Habituation, 903
 Haloperidol, 49
 Hamster 581
 HAS, 5
 Heart rate, 15
 Heptyl physostigmine, 865
 5-HIAA, 787
 High pressure neurological syndrome, 773
 High-fat feeding, 429
 Hippocampal slices, 119
 Hippocampus, 105, 437, 689, 781
 Holeboard, 373
 Homologous acetates, 983
 Homologous priming, 517
 Housing, 269
 5-HT, 729, 787, 813
 5-HT antagonism, 367
 5-HT receptors, 1021
 5-HT_{1A}, 635
 5-HT_{1A} receptor agonists, 43
 5-HT_{1A} receptors, 407
 5-HT_{1C} receptors, 605
 5-HT₂ receptors, 407, 605
 5-HT₃ receptors, 133, 509
 Human, 345
 Humans, 613
 Hunger, 1003
 6-Hydroxydopamine, 677, 1033
 4-Hydroxy-3-methamphetamine, 787
 Hyperactivity, 71
 Hyperalgesia, 695
 Hyperbaric conditions, 37
 Hyperglycemia, 383
 Hypoalgesia, 795
 Hypotension, 1029
 Hypothalamus, 535, 1003
 Hypothermia, 37, 55, 305, 625, 929
 Hypoxia, 991
 Imipramine, 91, 105, 167, 293, 769
 Immobilization, 373
 Incentive motivation, 955
 Independent ingestion, 955
 Individual differences, 877
 Indomethacin, 535
 Inferior colliculus, 683
 Ingestive behavior, 895
 Inhibitory G-protein, 383
 Insulin deficiency, 383
 Intact females, 635
 Intensification of abstinence syndrome, 575
 Intermediate memory, 717
 Intoxicated practice, 917
 Intracellular calcium, 641
 Intracerebroventricular infusions, 1029
 Intraoral catheter, 955
 Intrathecal, 591
 Intrathecal morphine, 761
 Ipsapirone, 729
 Isolation, 167
 Itch, 695
 Kainic acid, 155, 473
 Kappa agonist, 215
 Ketamine, 575, 829
 Ketanserin, 171, 605
 K-function, 747
 Khat, 549
 Kindling, 825
 LAS, 5
 Lateral head weaving, 671
 LD₅₀, 531
 Learned tolerance, 249, 257
 Learning, 205, 479, 781, 825, 883
 Learning enhancement, 31
 Lethality, 55

- LHRH, 143
Limbic system, 769
Lipid peroxidation, 649
Lipomobilization, 313
Lithium, 91
Locomotion, 269, 321, 513, 877
Locomotor activity, 545, 581, 699, 723, 773, 787, 923
Locus coeruleus, 809
Long-term potentiation, 689
Lordosis, 635, 737
Loss of the righting reflex, 653
LY-163502, 177
- M1 selective, 287
Macrophage inflammatory protein-1 (MIP-1), 535
Maharishi-4, 649
Maharishi-5, 649
Male and female Wistar rats, 923
Male rat sexual behavior, 813
Male rats, 143, 605
Male sex behavior, 123
Male sexual behavior, 219
MAO-B inhibitor, 297
Maternal behavior, 71, 201
Maze, 997
MDA, 183, 569, 787
MDL72222, 509
MDMA, 509, 619, 787, 813
Measure stability, 747
Mechanism of death, 625
Medial preoptic nucleus, 737
Median raphe nucleus, 761
Memory, 79, 205, 479, 689
Memory and learning, 997
Memory consolidation, 717
Memory retrieval, 31
Mesolimbic dopamine system, 71
Metabolic tolerance, 249
Metabolism, 383
Methadone, 487
N-Methyl-D-aspartate (NMDA), 479, 977
 α -Methyldopamine, 787
 α -Methyl-p-tyrosine, 437
Methylenedioxymethamphetamine, 509
3,4-Methylenedioxymethamphetamine, 813
 α -Methylepinephrine, 787
 α -Methylnorepinephrine, 787
Methyl scopolamine, 689
MHPG, 791
Mianserine, 293
Mice, 167, 197, 321, 531, 769, 865
Microdialysis, 781, 877
Microinjection, 43, 535
Midazolam, 129, 525, 977
Midazolam pharmacokinetics, 351
Midazolam self-administration, 351
Milacemide, 31
MK-801, 479
Monkey, 79
Morphine, 155, 191, 469, 487, 575, 581
Morphine anorexia, 279
Morphine sulfate, 591
Morris Water Maze, 297
Motor activity, 61
Motor impairment, 917
Motor performance, 351, 525
Mouse, 345
Mu opioids, 487
Mucosal chemoreception, 983
Muscarinic receptors, 437, 689
Muscarinic system, 25
Muscimol, 765
- NA levels, 437
NA utilization, 293
Naftidrofuryl oxalate, 997
Naloxone, 191, 415, 575, 581, 795
Narcosis, 55
Nasal irritation, 983
Nasal pungency, 983
Natural killer cell cytotoxicity, 361
NBM, 841
Neocortex, 345
Neonatal alcohol exposure, 423
Neonatal analgesia, 389
Neonatal undernutrition, 329
Neuroleptic, 549, 773, 895
Neuropeptide, 201, 581
Neuropeptide Y (NPY), 1003
Neurotoxicity, 569, 787, 813, 963
Neurotransmitters, 115
Nicotine, 197, 545, 929
Nictitating membrane response, 183, 503
Nifedipine, 325, 743
Nigrostriatal dopamine system, 71
Nimodipine, 781
NMDA, 155, 971
NMDA receptor, 31, 513, 829, 947
Nociception, 541
Noise, 373
Noise avoidance, 821
Nomifensine, 293
Nonhuman primate, 79
Nonreward, 275
Noradrenaline, 795, 809
Noradrenaline release, 191
Noradrenergic drugs, 79
Noradrenergic system, 1015
Norepinephrine, 21, 155, 361, 591, 737, 963
Novelty, 877
Novelty stress, 149
NPC 12626, 977
Nucleus, 619
Nucleus accumbens, 43, 71, 469
Nucleus basalis, 563
Nutrition, 115
- Obesity, 963, 1003
Odors, 983
Ofloxacin, 587
6-OHDA, 71
8-OH-DPAT, 729
Olfaction, 983
Olfactory brain, 437
Ontogeny, 517
Ontogeny of dopamine function, 955
Ontogeny of ingestion, 955
Open field, 43, 61, 367
Opiate antinociception, 641
Opiate tolerance, 761
Opiates, 215
Opioid mediation, 389
Opioids, 201, 421, 469
Oral dyskinesia, 677
Oral movements, 49
Organophosphate, 305, 851, 929
Oxiracetam, 197
Oxotremorine, 305, 929
Oxygen, 21
Oxygen consumption, 215
Oxytocin, 219
- Pain, 695, 889
Palatability, 895
Paraventricular nucleus, 177, 1003
Partial agonist, 287
Passive avoidance, 31, 563, 835, 841, 997
Pavlovian conditioning, 279
PCP receptors, 155
Penile erection, 123, 177
Pentazocine, 415
Pentobarbital, 249, 257, 705, 977
Pentylenetetrazol, 711
Pentylenetetrazole, 129, 521
Pentylenetetrazol-induced convulsions, 587
Peptides, 1003
Pharmacokinetics, 947
Phencyclidine, 947, 971, 977
Phencyclidine analogs, 947
Phencyclidine metabolism, 947
Phenobarbital, 305, 817
Phenylephrine, 737
Phenylpropanolamine, 755
Phenytol, 683
Phosphoinositide turnover, 287
Physostigmine, 337, 499, 929
Pigeons, 817, 935
Pigmented vs. albino, 665
Pilocarpine, 109
Pimozide, 895
Pirenperone, 605
Place navigation, 25
Plasma corticosterone, 191, 847
Platform, 211
Positive reinforcement, 955
Postnatal, 883
Prairie voles, 219
Prazosin, 795
Precipitated abstinence, 395
Preclinical study, 873
Predator-prey, 521
Preference, 1025
Prenatal alcohol, 389
Preoptic area, 535
Previous blockade of NMDA receptors, 575
Primate, 123, 991
Prolactin, 91, 373
Propranolol, 345, 597, 717, 795
Prostaglandin, 535
Psychological stress, 191
Psychomotor stimulant and benzodiazepine, 525
Psychopharmacology, 895
PTZ, 825
Punished behavior, 453
Punishment, 597, 977
Pup retrieval, 71
Puromycin, 689
Push-pull perfusion, 1003
PVN, 1003
Pyridostigmine, 613
- Quinelorane, 123, 177
Quinolinic acid, 473
Quinpirole, 449, 465, 517
Quipazine, 43
Quisqualate, 155
Quisqualic acid, 563
- Rabbit, 183, 503
Raclopride, 465
Radial maze, 287
Radiotelemetry, 457
Rapid eye movement sleep, 211

- Rapid tolerance, 917
Rat, 21, 37, 43, 61, 85, 91, 97, 129, 215, 351, 367, 415, 429, 453, 473, 487, 499, 597, 625, 665, 695, 769, 803, 825, 835, 859, 865, 883, 911, 917, 997, 1015
Rat brain, 205
Rat strains, 149, 705
Rearing behavior, 699, 923
Rears, 321
Receptor binding, 287
Receptor supersensitization, 517
Reinforcement, 465
Release, 835
Renin, 171
Respiration, 137
Respiratory control, 941
Respiratory depression, 625
Restraint, 373
Restraint stress, 847
Reward, 509
Rhesus monkeys, 123
Ritanserin, 171, 605, 911
Ro15-1788, 659, 791
Ro15-4513, 803
Rolipram, 321
Rotarod, 257
Rotational behavior, 1033
Route of administration, 581
- Salmon calcitonin, 641
Salt appetite, 171
Sartran, 1029
Satiety mechanism, 1003
SCH 23390, 367, 465, 699, 911
Schedule-induced polydipsia, 351
Schizophrenia, 743
Scopolamine, 25, 689, 835, 935, 997
Scratching, 695
Sedation, 321
Seizure, 625, 941
Selective breeding, 5
Self-administration, 133, 269, 569, 799, 911, 1011
Self-starvation, 85
Self-stimulation, 1, 465
Seminal emission, 177
Sensitization, 903
Sensory, 265
Serotonin, 25, 43, 115, 133, 591, 605, 619, 635, 671, 765, 963, 991
Serotonin syndrome, 407
Serum transferrin, 443
Sex behavior, 737
Sex differences, 923
- Sexual behavior, 71, 605, 635
Shaking behavior, 407, 1021
Sham feeding, 1025
Shuttle box, 825
Sialic acid, 443
SKF 38393, 367, 449, 465
Skin jerks, 407
Sleep time, 5, 653
Smoking, 15, 265, 889
Sodium depletion, 171
Sodium valproate, 683
Soman, 305, 851, 929
Somatostatin, 541
Spatial memory, 781
Species-specificity, 769
Spectral analysis of heart rate, 613
Spinal, 155
Spinal cord, 591
Spinal opiate analgesia, 761
Spontaneous behavior, 747
Spontaneously hypertensive rat, 1029
Sprague-Dawley rats, 389, 747
Squirrel monkey, 977, 1011
Startle response, 903
Steroid baseline, 143
Stimulus control, 817
Stimulus properties of drugs, 5
Stimulus salience, 597
Streptozotocin, 383
Stress, 265, 361
Stress-related hormones, 717
Striatum, 97
Subcortex, 437
Subjective response, 889
Substance P, 155, 473, 541, 695
Substantia nigra, 109, 1033
Successive discrimination, 275
Suckling deficits, 423
Sucrose, 895
(-)-Sulpiride, 699
Supersensitivity, 105, 677
Sweet taste, 955, 1025
Switch-off behavior, 683
Sympathomimetics, 755
Synaptosomes, 641
- Tachypnea, 941
Tail flick, 761
Tail shock, 373
Tandospirone, 729
Tardive dyskinesia, 49, 743
Taste reactivity, 895
Telemetry, 305
Temperature, 137, 457
- Temperature challenge, 457
Temporal memory, 935
Tetrahydroaminoacridine, 499
THA, 563, 841
Theophylline, 345
Thermodynamic activity, 983
Thermogenesis, 21, 755
Thermoregulation, 37, 535, 929, 1003
Thiol proteases, 495
Thresholds, 983
Thromboxane, 535
Time structure, 747
Time, 935
T-maze, 689
Tolerance, 15, 305, 329, 407, 487, 659, 705, 711, 851, 1021
Toxicity, 531
Turnover rate, 671
Two-bottle taste aversion test, 161
Tyrosine, 755
- U50,488H, 215
U-78875, 379
Ultrasonic vocalizations, 389
Upper airway, 137
Urethane, 625
- Vasoactive intestinal polypeptide, 695
Ventral tegmental area, 469
Ventromedial hypothalamus, 635
Ventromedial nucleus, 737
VER, 851
Vigabatrin, 205
Visual evoked potential, 665
Visual recognition task, 991
Voluntary wheel running, 821
- Water intake, 1003
Water maze, 479, 829
Water maze relearning, 563
Weakly reinforced training, 717
Wild running, 683
Withdrawal signs, 659
Working memory, 935
Wy-47,846, 729
Wy-48,723, 729
- Yawning, 517
YM-09151-2, 911
Yohimbine, 313, 795
- Zacopride, 729
Zetidoline, 367
ZK 93426, 553

AUTHOR INDEX

- Aaltonen, M., 563
Abelson, M., 287
Abraini, J. H., 773
Advocat, C., 761
Akselrod, S., 613
Albertson, T. E., 625
Alcalay, M., 613
Ali, S. F., 619
Alkana, R. L., 457
Alling, K., 817
- Al-Tajir, G., 109
Amit, Z., 55, 269
Ammassari-Teule, M., 197
Anisman, H., 361
Antonioni, K., 61
Aoki, T., 541
Apfelbaum, M., 215
Appel, N. M., 963
Aragon, C. M. G., 55
Aricioğlu, F., 575
- Arjune, D., 429
Armario, A., 373
Arneric, S. P., 337
Asai, S., 499
Aulakh, C. S., 91
- Babu, S. R., 337
Bagri, A., 683
Balasch, J., 373
Balster, R. L., 971, 977
- Banas, C., 695
Barron, S., 423
Battaglia, M., 197
Battaini, F., 835
Beal, M. F., 473
Beaugé, F., 443
Beckel, M., 559
Becker, A., 825
Becker, H. C., 803
Behm, F., 265

- Bejanian, M., 457
 Bellinger, L. L., 161
 Bender, R., 287
 Beninger, R. J., 97
 Benjamini, Y., 613
 Benson, H. D., 279
 Bentley, G., 865
 Bergamaschi, S., 835
 Berge, O.-G., 37
 Bergman, J., 1011
 Berlan, M., 313
 Berridge, C. W., 877
 Betouille, D., 215
 Beyer, C., 695
 Bigelow, L. B., 743
 Bilsky, E. J., 509
 Bitrán, M., 917
 Boast, C. A., 287
 Bodnar, R. J., 429
 Borelli, G., 297
 Bourdin, C., 443
 Bourguignon, J.-J., 321
 Bourre, J. M., 443
 Bowen, W. D., 429
 Boyle, A. E., 269
 Bradberry, C. W., 877
 Brandeis, R., 297
 Bridges, R. S., 201
 Bridson, S., 935
 Brigant, L., 215
 Britton, D. R., 911
 Bruhwyler, J., 367
 Brus, R., 517
 Bryson, R., 821
 Buccafusco, J. J., 79

 Caba, M., 695
 Cadel, S., 297
 Caggiula, A. R., 15
 Cai, B., 167, 699
 Cain, W. S., 983
 Caldarola-Patuszka, M., 635
 Callahan, M., 559
 Carino, M. A., 449
 Carlisle, H. J., 21
 Carr, K. L., 883
 Carter, C. S., 219
 Caskey, N. H., 265
 Castellano, C., 197
 Cesar, S. S., 581
 Chakravarty, A. K., 847
 Chamberlin, J. R., 821
 Chan, A. W. K., 659
 Chance, W. T., 115
 Chapman, M. A., 49
 Chau, A., 705
 Chiu, T. H., 711
 Chleide, E., 367
 Cho, A. K., 947
 Church, A. C., 689
 Ciarleglio, A., 531
 Clemens, L. G., 737
 Clement, J. G., 305, 929
 Coen, K. M., 799
 Coenen, A. M. L., 415
 Cohen, C. A., 329
 Commetto-Muñiz, J. E., 983
 Contrera, J. F., 963
 Corrigan, W. A., 799
 Crisp, T., 591
 Crowe, S. F., 717
 Culp, S., 963

 Curzon, P., 911

 Dailey, A., 1021
 D'Angelo, C. P., 479
 Davis, B. L., 737
 Dawson, G. R., 865
 de Beun, R., 143
 de Boer, S. F., 149
 de Groot, G., 149
 DeLander, G. E., 155
 Delarge, J., 367
 De Lugt, D., 889
 DeNoble, K. F., 991
 DeNoble, V. J., 991
 Derlet, R. W., 625
 De Souza, E. B., 963
 Dilsaver, S. C., 553
 Dirksen, R., 415
 Di Scala, G., 683
 Dobrowski, S., 649
 Dollison, A., 1021
 Dornan, W. A., 813
 Draper, F., 865
 Droge, M., 635
 Dube, S. N., 337
 Dufresne, R. L., 1
 Dwivedi, C., 649

 Eaton, R. C., 177
 Ehlers, C. L., 513
 Eikelboom, R., 895
 Elsworth, J. D., 791
 Engberg, G., 809
 Enginar, N., 587
 Engineer, F. N., 649
 Epstein, L. H., 15
 Eroglu, L., 325, 587

 Falk, J. L., 351, 525
 Felicio, L. F., 201
 Ferko, A. P., 653
 Finn, D. A., 457
 Fischer, J. E., 115
 Flexner, J. B., 689
 Flexner, L. B., 689
 Foderaro, M. A., 581
 Foo, H., 795
 Frank, C., 119
 Freed, W. J., 743

 Gadau, C., 825
 Galitzky, J., 313
 Garcia-Cabrera, I., 37
 Gauvin, D. V., 521
 Geerts, N. E., 143
 Gentili, L., 171
 Ghi, P., 437
 Giacomo, D., 287
 Giaroni, G., 835
 Gibbs, J., 1025
 Gibbs, M. E., 717
 Gil, M., 373
 Gill, K., 269
 Giroux, M. L., 553
 Gong, L., 677
 Gorbacheva, E. N., 873
 Gormezano, I., 183, 503
 Gorzalka, B. B., 605
 Gough, B., 619
 Govoni, S., 835
 Grecksch, G., 825
 Greenberg, D., 1025

 Griebel, G., 321
 Gruen, R. J., 877
 Guo, T.-Z., 383
 Gutierrez, Y. R., 495

 Haass, M., 91
 Haertzen, C. A., 723
 Hagan, M. M., 421
 Hajós, M., 809
 Hale, R. L., 803
 Halonen, T., 205
 Hansen, S., 71
 Harding, J. W., 1029
 Harper, R. K., 137, 941
 Harper, R. M., 137, 941
 Harsing, L., 545
 Harthon, C., 71
 Hashim, A., 545
 Hearn, W. L., 531
 Helmstetter, F. J., 903
 Herting, R. L., 31
 Hijzen, T. H., 859
 Hill, J. L., 91
 Hiramatsu, M., 947
 Holloway, F. A., 521
 Holson, R. R., 619
 Horita, A., 449
 Hsu, F.-L., 787
 Hull, E. M., 177
 Hull, K. M., 755

 Ida, Y., 791
 Imamura, L., 699
 Irwin, J., 361
 Ishii, Y., 499
 Ishikawa, K., 499
 Iversen, S. D., 865
 Izraeli, S., 613

 Jackson, W. J., 79
 Jäkälä, P., 25
 Jansen, E., 143
 Järbe, T. U. C., 129
 Jerome, C., 1025
 Jones, B. L., 457
 Jortani, S. A., 977
 Josselyn, S. A., 97
 Joyal, C. C., 829

 Kadar, T., 781
 Kafetzopoulos, E., 61
 Kalant, H., 705, 917
 Kamei, J., 541
 Kameyama, T., 947, 997
 Kaneko, W., 513
 Kant, G. J., 479
 Kapitsopoulos, G., 487
 Kapon, Y., 297
 Kasuya, Y., 541
 Katz, J. L., 813
 Kebabian, J. W., 911
 Kehoe, P., 389
 Kelly, S. J., 423
 Kerkman, D., 911
 Kernan, W. J., 747
 Khanna, J. M., 705
 Kiraç, R., 325
 Kirch, D. G., 743
 Kirkpatrick-Steger, K., 183
 Klenk-Majewska, B., 293
 Knott, V. J., 889
 Kobayashi, H., 495

 Kogure, M., 499
 Koivisto, E., 1015
 Komisaruk, B. R., 695
 Kong, R. M., 781
 Kostowski, W., 43
 Kostrzewa, R. M., 517, 677
 Koyuncuoğlu, H., 575
 Kreeger, T. J., 559
 Krimmer, E. C., 1
 Kubo, T., 499
 Kucharik, R. F., 729
 Kulkosky, P. J., 581

 Lahtinen, H., 205
 Lajtha, A., 545
 Lalonde, R., 829
 Langan, M. C., 659
 Lau, C. E., 351, 525
 Leaton, R. N., 903
 Lee, H. H., 883
 Lee, J. M., 765
 Leeb, K., 895
 Leone, P., 469
 Leong, F. W., 659
 Leventer, S., 287
 Levin, E. D., 265
 Levine, A. S., 559
 Levy, A., 781
 Levy, M., 1021
 Liégeois, J.-F., 367
 Lieberman, H. R., 781
 Lima, L., 671
 Löfberg, L., 71
 Longoni, A., 835
 Lookingland, K. J., 737
 Lopez, C. M., 835
 Lorens, S. A., 765
 Luchetti, G., 171
 Lukkarinen, K., 1015
 Lumley, L. A., 177

 McArthur, S., 287
 McKenzie, S. J., 15
 McLeod, W. S., 85
 McNaughton, N., 275

 Mackenzie, R. G., 911
 MacKenzie-Taylor, D. R., 249, 257
 Madras, B. K., 1011
 Magoun, J., 761
 Mahalati, K., 219
 Maher, T. J., 755
 Makhay, M. M., 487
 Malatynska, E., 553
 Mallick, B. N., 211
 Mally, J., 345
 Mandenoff, A., 215
 Mann, P. E., 201
 Mansbach, R. S., 971, 977
 Manzanares, J., 737
 Markert, L. E., 569
 Markowski, V. P., 177
 Marshall-Goodell, B., 503
 Marti, J., 373
 Martin, W. R., 395
 Mash, D. C., 531
 Massi, M., 171
 Matsumoto, K., 167, 699
 Matthies, H., 825
 Maurer, S., 287
 Maze, B., 383

- Maze, M., 383
 Mehta, O., 287
 Melchior, J. C., 215
 Melville, L. D., 1025
 Mendel, V. E., 161
 Mercier, M., 367
 Meyer, M. E., 923
 Miñano, F. J., 535
 Misslin, R., 321
 Mitsushio, H., 765
 Mizoguchi, K., 191
 Molinengo, L., 437
 Mollenauer, S., 821
 Montanez, S., 635
 Montastruc, P., 313
 Moore, K. E., 737
 Morris, H., 287
 Moses, J., 177
 Moss, D. E., 421, 495
 Moyer, J. A., 287, 729
 Mullenix, P. J., 747
 Murphy, D. L., 91
 Murray, C. E., 1029
 Myers, R. D., 535, 1003
- Nabeshima, T., 947, 997
 Nakajima, S., 465
 Nemeroff, C. B., 765
 Ng, K. T., 717
 Ni, H., 941
 Nickel, M., 817
 Nowak, G., 769
 Nuygen, T., 31
- Ogawa, S.-I., 997
 Oggero, L., 437
 Ohhashi, Y., 541
 Ohta, H., 167, 699
 Oien, T. T., 379
 Okanoya, K., 219
 Olson, K. G., 641
 O'Regan, N. B., 465
 Orsetti, M., 437
 Ossowska, G., 293
- Pagella, P. G., 865
 Palejko, W., 43
 Panickar, K. S., 275
 Paris, J. M., 765
 Parker, L., 895
 Paul, I. A., 769
 Pchelintsev, M. V., 873
 Peltier, R., 133
 Penetrante, F., 659
 Pennanen, A., 1015
 Perez, R. G., 495
 Perkins, K. A., 15
 Perni, V. C., 591
 Philippens, H. C. H. M., 851
 Płaźnik, A., 43
 Pluchino, R. S., 407
 Pockock, D., 469
- Pol, O., 373
 Poling, A., 817
 Pomerantz, S. M., 123
 Pranzatelli, M. R., 407, 1021
 Proietti, M. L., 119
 Puri, S., 847
- Quartermain, D., 31
- Rabchenuk, S. A., 903
 Rauch, T. M., 781
 Ray, A., 847
 Rech, R. H., 249, 257
 Reid, L. D., 509
 Reigel, A. L., 991
 Ricaurte, G. A., 813
 Riccitelli, A. J., 1
 Richard, C. A., 137, 941
 Richards-Hill, R., 635
 Riekkinen, M., 841
 Riekkinen, P., 25, 205, 563, 841, 1015
 Riekkinen, P., Jr., 25, 205, 563, 841, 1015
 Rijnders, H. J., 129
 Riley, E. P., 423
 Ritchie, J. C., 765
 Roberts, D. C. S., 569
 Robinson, T. N., III, 479
 Robledo, P., 513
 Rockman, G. E., 85
 Ronkainen, A., 205
 Roscoe, A. K., 1003
 Rose, J. E., 265
 Rose, S., 531
 Rosenberg, H. C., 711
 Rostain, J. C., 773
 Roth, R. H., 791, 877
 Rycroft, W., 865
- Sabb, A., 287
 Sagratella, S., 119
 Saija, A., 171
 Salmon, P., 597
 Sandner, G., 683
 Sansone, M., 197
 Santi, A., 935
 Sapir, M., 297
 Satoh, T., 167
 Schanley, D. L., 659
 Schechter, M. D., 549
 Schellenberg, F., 443
 Schenk, S., 133
 Schmitz, D. A., 947
 Schnur, P., 581
 Schrak, L. M., 991
 Schwarzkopf, S. B., 553
 Scott, A., 883
 Scotti de Carolis, A., 119
 Seal, U. S., 559
 See, R. E., 49
 Sen, P., 847
- Sershen, H., 545
 Sethy, V. H., 379
 Seyrig, J. A., 215
 Shah, G., 705
 Sharma, H. M., 649
 Sheu, J., 31
 Shibanoki, S., 499
 Shimizu, T., 191
 Shoemaker, W., 389
 Shukitt-Hale, B., 781
 Siegel, J., 665
 Silverman, P. B., 1029
 Sirviö, J., 25, 205, 563, 841, 1015
 Sisson, D. F., 665
 Skolnick, P., 769
 Slangen, J. L., 129, 143
 Slikker, W., Jr., 619
 Sloan, J. W., 395
 Śmiałowski, A., 105
 Smith, B. R., 269
 Smith, G. P., 955, 1025
 Smith, J. A., 15
 Somani, S. M., 337
 Spanos, L. J., 591
 Sparber, S. B., 329
 Spealman, R. D., 1011
 Speck, C., 821
 Spigelman, M. N., 85
 Spivak, K., 55
 Stafinsky, J. L., 591
 Stark, L. G., 625
 Starr, M. S., 109
 Stefański, R., 43
 Steigerwald, E. S., 487
 Stillman, M. J., 781
 Stone, T. W., 345
 Storch, F., 287
 Straw, G. M., 743
 Suddath, R. L., 743
 Svensson, K., 71
 Syapin, P. J., 457
- Tanaka, M., 191
 Tang, M., 351
 Terreberry, R. R., 137
 Terry, P., 597
 Thakkar, M., 211
 Thompson, J. T., 177
 Tietz, E. I., 711
 Tochner, Z., 613
 Tomei, C., 773
 Tonkiss, J., 329
 Trabucchi, M., 835
 Trampus, M., 119
 Tran, M.-A., 313
 Tseng, C.-C., 625
 Tsuda, A., 191
 Tyrka, A., 955
- Uphouse, L., 635
 Uram, M., 591
- Valentino, D. A., 1
 Valjakka, A., 1015
 Valsecchi, B., 297
 van de Poll, N. E., 143
 van der Gugten, J., 149
 van der Laan, J. W., 149
 Vander Linden, S., 183
 Van Haaren, F., 923
 Van Luijelaar, L. J. M., 415
 Vanwersch, R. A. P., 851
 Vécsei, L., 473
 Vigorito, M., 351
 Virtanen, R., 1015
 Vizcaino, M., 535
 Vogel, E., 321
- Wagner, J., 531
 Wahl, J. J., 155
 Wala, E. P., 395
 Wallach-Kapon, R., 613
 Wallin, E., 71
 Watanabe, H., 167, 699
 Watson, N. V., 605
 Weatherford, S. C., 1025
 Weaver, M. F., 591
 Weider, J. M., 883
 Weill, J., 443
 Welch, S. P., 641
 Westbrook, 795
 Westenberg, I. S., 665
 White, S. M., 729
 Willetts, J., 977
 Williams, J. E. G., 911
 Wise, R. A., 469
 Witkin, J. M., 453
 Witkin, K. M., 453
 Witt, D. M., 219
 Wolgin, D. L., 279
 Wolthuis, O. L., 851
 Woudenberg, F., 859
 Wozniak, K. M., 91
 Wright, J. W., 1029
 Wright, W. L., 479
 Wyatt, R. J., 743
- Yeh, S. Y., 723, 787
 Ylinen, A., 205
 Yokoo, H., 191
 Yoshida, M., 191
 Young, A. M., 487
 Young, B. J., 903
- Zaczek, R., 963
 Zalcman, S., 361
 Żebrowska-Łupina, I., 293
 Zhang, F., 115
 Zimmerberg, B., 883
 Zohar, J., 91
 Zvartau, E. E., 873
 Zylan, K. D., 21